StudyFinder

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALTO-300 WITH AN OPEN-LABEL EXTENSION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER

Status: Recruiting

The purpose of this study is to evaluate the safety and effectiveness of ALTO-300, an investigational medication being studied for adults with Major Depressive Disorder (MDD). This study will compare ALTO-300 to a placebo to learn more about how the medication may improve symptoms of depression and to identify factors that may help predict who is most likely to benefit from treatment.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• ages 18-70 years old
• diagnosed with moderate to severe major depressive disorder (MDD)
• currently taking one approved antidepressant medication (SSRI, SNRI, or bupropion) for at least 6 weeks with no recent dose changes
Exclusion Criteria:

• diagnosed with fibromyalgia
• pregnant or breastfeeding
Conditions:

Mental Health & Addiction

Keywords:

agomelatine, ALTO-300, depression, Major Depressive Disorder, MDD

Study Contact: Dariush Kaveh - kave0005@umn.edu
Principal Investigator: Cristina Albott
Phase: PHASE2
IRB Number: STUDY00027511
See this study on ClinicalTrials.gov

Back